Inactive Instrument

VIVUS, Inc.

VVUSQ

US9285513084

First Motion for Exclusivity Period Extension Approved For VIVUS, Inc.

Published on 11/16/2020 at 11:00 pm EST

S&P Capital IQ

VIVUS, INC.

+1.56%

The US Bankruptcy Court granted an order for the extension of the exclusivity periods for VIVUS, Inc. on November 17, 2020. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 75 days i.e. up to January 18, 2021 and March 19, 2021, respectively.

Latest news about VIVUS, Inc.

Jan. 26	VIVUS LLC Announces the Results of a Randomized Trial Evaluating the Effect of QSYMIA	CI
Jan. 07	VIVUS Introduces Lower Pricing on QSYMIA at Costco Locations Across Hawaii	CI
25-09-04	VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome	CI
25-05-27	VIVUS Announces Qsymia Now Available at Costco Pharmacies Nationwide	CI
25-04-14	VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma	CI
25-03-10	VIVUS Launches QSYMIA in the United Arab Emirates	CI
24-10-23	VIVUS Announces Label Update for QSYMIA	CI
24-05-30	Vivus, Inc. Announces the Publication of New Clinical Trial Data Demonstrating That Pancreaze Helped to Stabilize Weight in Patients Undergoing Chemotherapy for the Treatment of Pancreatic Ductal Adenocarcinoma	CI
24-04-22	VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth	CI
23-11-28	VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA	CI
23-01-10	VIVUS, Inc. Promotes Santosh T. Varghese to President VIVUS Global Pharmaceutical Development	CI
22-07-20	FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17	CI
20-12-10	VIVUS, Inc. Emerged from Bankruptcy	CI
20-12-10	Revised Second Amended Reorganization Plan & Disclosure Statement Approved for VIVUS, Inc.	CI
20-11-16	First Motion for Exclusivity Period Extension Approved For VIVUS, Inc.	CI

Chart VIVUS, Inc.

Duration

Period

VVUSQ: Dynamic Chart

Company Profile

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Employees

Sector

Pharmaceuticals

More about the company